Clinical Trials Logo

Pancreatic Neuroendocrine Tumor clinical trials

View clinical trials related to Pancreatic Neuroendocrine Tumor.

Filter by:

NCT ID: NCT06167421 Not yet recruiting - Clinical trials for Pancreatic Neuroendocrine Tumor

Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This study aims to compare the surgical outcomes of laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique versus the Warshaw technique. The primary focus is on the rates of unplanned splenectomy, occurrence of severe complications, as well as intraoperative and perioperative outcomes of both techniques.

NCT ID: NCT06158516 Not yet recruiting - Clinical trials for Pancreatic Neuroendocrine Tumor

A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

Start date: November 30, 2023
Phase: Phase 2
Study type: Interventional

pNENs still have a risk of recurrence after radical resection, and the overall recurrence and metastasis rate is as high as 13.7%-36.2% in China. At present, there is no standard adjuvant therapy for pNEN, and prospective studies are still lacking. This study was a randomized, double-blind, placebo-controlled, multicenter clinical trial to explore the efficacy and safety of surufatinib in the adjuvant treatment of pNET, in order to further improve the prognosis of patients and to provide high-quality research evidence for adjuvant therapy.

NCT ID: NCT06141369 Recruiting - Clinical trials for Pancreatic Neuroendocrine Tumor

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

Start date: January 13, 2024
Phase: N/A
Study type: Interventional

Treatment of advanced endocrine tumors, including adrenal corticocarcnioma (ACC), medullary thyroid carcinoma (MTC), thymic neuroendocrine tumor and pancreatic neuroendocrine tumor is challenging. Previous genomic profiling studies showed they presented a number of somatic mutations. The tumors Individualized mRNA neoantigen vaccine provide a promising solution since a significant portion of these tumors showed high quality of tumor specific neoantigen. The primary objective is to observe and evaluate the safety and tolerability of individualized mRNA neoantigen vaccine (mRNA-0523-L001) for the treatment of advanced endocrine tumors, failure of standard treatment or no standard treatment currently available. The secondary objective is to observe the preliminary efficacy of mRNA-0523-L001 for the treatment of advanced endocrine tumors, failure of standard treatment or no standard treatment currently available, including: 1. Neoantigen-specific CD4+ and CD8+ T lymphocyte responses induced by mRNA-0523-L001; 2. Objective response rate (ORR) and disease control rate (DCR) of tumors; 3. Progression-free survival (PFS).

NCT ID: NCT06121622 Recruiting - Clinical trials for Pancreatic Neuroendocrine Tumor

Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours

3DPanNET
Start date: January 16, 2024
Phase:
Study type: Observational

The goal of this prospective observational study is to generate new personalised 3D preclinical models of pancreatic neuroendocrine tumors. The models will be exploited for studying the mechanisms underlying disease development and progression, as well as for performing drug testing. For the development of the newly proposed models, patients' surgical specimens will be evaluated by the Pathological Unit. If the presence of pathological material in excess, not required for the routine diagnostic procedure, is confirmed, such material will be employed for the generation of the proposed personalised models.

NCT ID: NCT06041009 Recruiting - Clinical trials for Pancreatic Neoplasms

Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations

Start date: December 20, 2023
Phase:
Study type: Observational

This is a prospective cohort study. The investigators enroll subjects with pancreatic ductal adenocarcinoma (PDAC), individuals at high risk for PDAC, patients with other pancreatic diseases, patients with CA19-9 elevation and controls without pancreatic disease. This study aims to establish a diagnostic prediction model by using elastase 1, common clinical serological examinations, and imaging examinations including endoscopic ultrasonography (EUS), and to explore the diagnostic ability of the model in the high-risk population of PDAC. Besides, the investigators search for new biomarkers by multi-omics studies of serum and pancreatic tissues to further improve the diagnostic performance of this model. In conclusion, this study seeks a robust diagnostic prediction model to diagnose PDAC, especially early resectable PDAC.

NCT ID: NCT06024343 Not yet recruiting - Clinical trials for Pancreatic Neuroendocrine Tumor

Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the impact of concomitant main pancreatic duct repair or reconstruction during minimally invasive pancreatic tumor enucleation on long-term patient prognosis and quality of life.

NCT ID: NCT05997056 Recruiting - Clinical trials for Neuroendocrine Tumors

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Start date: November 7, 2023
Phase: Phase 2
Study type: Interventional

A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors

NCT ID: NCT05988918 Not yet recruiting - Clinical trials for Pancreatic Adenocarcinoma

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Start date: May 2024
Phase: Phase 2
Study type: Interventional

This protocol will enroll patients with pancreatic adenocarcinoma and adenosquamous carcinoma (Cohort 1), gastrointestinal/pancreatic neuroendocrine neoplasms with Ki-67 > 20% (Cohort 2) and neuroendocrine prostate carcinoma (Cohort 3)). Each cohort will have its own interim analysis after enrollment of 10 patients. Subjects will be given a one-month (28 day) supply of study drug (ESK981). Subjects will be instructed to take 4 capsules, with or without food, once per day for 5 consecutive calendar days, then take a drug holiday for 2 consecutive days before repeating the 5 days on-2 days off cycle in sets of 4 weeks or 28 calendar days. Subjects will be asked to keep a pill diary noting the date they take their study drug.

NCT ID: NCT05847855 Not yet recruiting - Clinical trials for Pancreatic Neuroendocrine Tumor

Multi-dimensional Fragmentomic Assay for Early Detection of Pancreatic Neuroendocrine Tumors

Start date: April 27, 2023
Phase:
Study type: Observational

This prospective study aims to evaluate the sensitivity and specificity of an integrated model using fragmentomic profiles of plasma cell-free DNA for early detection of pancreatic neuroendocrine tumors.

NCT ID: NCT05800106 Completed - Clinical trials for Renal Cell Carcinoma

A Bioequivalence Study of Sunitinib Malate Capsules.

Start date: December 4, 2018
Phase: Phase 1
Study type: Interventional

A randomized, open, two-period, two-sequence crossover trial design used to assess the pharmacokinetics and safety of Sunitinib Malate Capsules in healthy volunteers under fed condition, and compare the bioequivalence of Sunitinib Malate Capsules produced by Pfizer and Chia Tai Tianqing Pharmaceutical Group Co., Ltd, respectively.